A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3700 in Healthy Subjects
Latest Information Update: 12 Nov 2014
Price :
$35 *
At a glance
- Drugs ASP 3700 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Astellas Pharma Europe Ltd
- 10 Nov 2014 New trial record
- 09 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.